StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $1.39 | $1.46 | +5.04% | 0.2M |
| 05-14 | $1.59 | $1.68 | +5.66% | 4.3M |
| 05-15 | $1.66 | $1.55 | -6.63% | 0.9M |
| 05-18 | $1.55 | $1.49 | -3.87% | 0.3M |
| 05-19 | $1.47 | $1.44 | -2.38% | 0.1M |
No sell-side coverage available for INMB.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
Fundamentals not available for INMB.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $50.00K | $50.00K | $50.00K | $50.00K |
Operating Income | $-47.38M | $-41.91M | $-34.48M | $-9.90M |
Net Income | $-45.93M | $-40.67M | $-24.46M | $-9.74M |
EPS (Diluted) | $-1.86 | $-1.68 | $-1.49 | $-0.43 |
Total Assets | $32.35M | $33.36M | $37.68M | $37.80M |
Total Liabilities | $8.83M | $7.98M | $8.82M | $8.13M |
Cash & Equivalents | $24.75M | $27.73M | $33.37M | $19.34M |
Free Cash Flow OCF − CapEx | $-23.62M | $-20.54M | $-14.90M | Not available |
Shares Outstanding | 26.59M | 26.59M | 26.59M | 22.93M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.